(Q61794170)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21917307%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21917307%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21917307%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Robin L Jones

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21917307%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Maurizio D'Incalci

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21917307%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Angelo Paolo Dei Tos

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21917307%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Paolo Giovanni Casali

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21917307%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

5

Silvana Pilotti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21917307%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

2

Federica Grosso

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21917307%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

4

Susana Banerjee

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21917307%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Francesco Raspagliesi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21917307%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Ian Judson

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21917307%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

English

0 references

publication date

13 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21917307%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21917307%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

123

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21917307%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21917307%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

553-556

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21917307%20AND%20SRC:MED&resulttype=core&format=json

Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

The Prognostic Significance of ‘Stage, Tumor Size, Cellular Atypia and DNA Ploidy in Uterine Leiomyosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

The role of radiation therapy in the management of uterine sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Uterine leiomyosarcoma: analysis of treatment failures and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Resection of pulmonary metastases from uterine sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Optimal management of uterine leiomyosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Temozolomide in uterine leiomyosarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.016

10.1016/J.YGYNO.2011.08.016

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21917307%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference